Table I.
Subject characteristics and test results
| Subject no. | Age (years) | Sex | PID diagnosis | Antibody deficiency | Ig therapy | SARS-CoV-2 mRNA vaccine | Time between second vaccine dose and serology (weeks) | SARS-CoV-2 spike protein IgG after vaccine | SARS-CoV-2 ACE2 blocking activity | SARS-CoV-2 IGRA |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 21 | M | Agammaglobulinemia | Yes | Yes | Pfizer-BioNTech | 4.43 | Negative | — | Positive |
| 2 | 30 | M | XLA | Yes | Yes | Moderna | 4.00 | Negative | — | Positive |
| 3 | 30 | F | CVID | Yes | Yes | Pfizer-BioNTech | 5.86 | Positive | 50-60% | Positive |
| 4 | 32 | F | CVID | Yes | Yes | Pfizer-BioNTech | 8.71 | Negative | — | Positive |
| 5 | 38 | F | CVID | Yes | Yes | Pfizer-BioNTech | 4.14 | Positive | 40-50% | Positive |
| 6 | 40 | M | CVID | Yes | Yes | Moderna | 5.57 | Positive | 40-50% | Positive |
| 7 | 41 | F | CVID | Yes | Yes | Pfizer-BioNTech | 9.14 | Positive | <10% | Positive |
| 8 | 53 | M | CVID | Yes | Yes | Moderna | 9.43 | Negative | — | Positive |
| 9 | 56 | M | CVID | Yes | Yes | Pfizer-BioNTech | 15.00 | Positive | <10% | Negative |
| 10 | 58 | F | CVID | Yes | Yes | Pfizer-BioNTech | 4.86 | Positive | <10% | Positive |
| 11 | 59 | M | CVID | Yes | Yes | Pfizer-BioNTech | 7.00 | Negative | — | Negative |
| 12 | 60 | F | CVID | Yes | Yes | Pfizer-BioNTech | 9.57 | Positive | 30-40% | Positive |
| 13 | 63 | F | CVID | Yes | Yes | Moderna | 9.86 | Positive | 30-40% | Positive |
| 14 | 71 | F | CVID | Yes | Yes | Moderna | 10.71 | Positive | 20-30% | Positive |
| 15 | 72 | M | CVID | Yes | Yes | Moderna | 17.57 | Positive | NA | Positive |
| 16 | 73 | F | CVID | Yes | No | Pfizer-BioNTech | 24.71 | Positive | <10% | Positive |
| 17 | 79 | F | CVID | Yes | Yes | Pfizer-BioNTech | 11.29 | Positive | <10% | Negative |
| 18 | 39 | F | HGG | Yes | Yes | Moderna | 9.57 | Positive | 60-70% | Positive |
| 19 | 55 | F | HGG | Yes | Yes | Pfizer-BioNTech | 6.85 | Negative | — | Positive |
| 20 | 67 | F | HGG | Yes | Yes | Pfizer-BioNTech | 9.43 | Positive | <10% | Positive |
| 21 | 75 | M | HGG | Yes | Yes | Moderna | 16.77 | Negative | — | Negative |
| 22 | 53 | F | SAD | Yes | Yes | Pfizer-BioNTech | 6.57 | Positive | 40-50% | Positive |
| 23 | 74 | F | SAD | Yes | Yes | Moderna | 14.43 | Positive | 10-20% | Positive |
| 24 | 43 | M | GS with HGG | Yes | Yes | Pfizer-BioNTech | 9.86 | Negative | — | Negative |
| 25 | 65 | F | GS with HGG | Yes | Yes | Pfizer-BioNTech | 5.86 | Negative | — | Positive |
| 26 | 68 | F | GS with HGG | Yes | Yes | Moderna | 19.00 | Negative | — | Negative |
| 27 | 70 | F | GS with HGG | Yes | Yes | Pfizer-BioNTech | 19.14 | Negative | — | Negative |
| 28 | 39 | M | Hyper IgM syndrome | Yes | Yes | Pfizer-BioNTech | 15.71 | Negative | — | Positive |
| 29 | 40 | M | Hyper IgM syndrome | Yes | Yes | Pfizer-BioNTech | 13.14 | Negative | — | Positive |
| 30 | 19 | M | CTLA-4 deficiency | Yes | Yes | Pfizer-BioNTech | 6.43 | Negative | — | Positive |
| 31 | 29 | M | PIK3R1 | Yes | Yes | Pfizer-BioNTech | 18.25 | Negative | — | — |
| 32 | 26 | F | Ataxia telangiectasia | Yes | Yes | Pfizer-BioNTech | 5.71 | Negative | — | — |
| 33 | 20 | M | ATP6AP1 gene/immunodeficiency 47 | Yes | Yes | Pfizer-BioNTech | 4.43 | Negative | — | Positive |
GS, Good syndrome; HGG, hypogammaglobulinemia; NA, not applicable; SAD, specific antibody deficiency; XLA, X-linked agammaglobulinemia.